Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

Author:

Rosiñol Laura1ORCID,Oriol Albert2ORCID,Rios Rafael3ORCID,Sureda Anna4,Blanchard María Jesús5,Hernández Miguel Teodoro6,Martínez-Martínez Rafael7,Moraleda Jose M.8,Jarque Isidro9ORCID,Bargay Juan10,Gironella Mercedes11,de Arriba Felipe12,Palomera Luis13,González-Montes Yolanda14,Martí Josep M.15,Krsnik Isabel16ORCID,Arguiñano Jose M.17,González Maria Esther18,González Ana Pilar19ORCID,Casado Luis Felipe20ORCID,López-Anglada Lucia21ORCID,Paiva Bruno22,Mateos Maria-Victoria23,San Miguel Jesus F.22ORCID,Lahuerta Juan-José21,Bladé Joan1

Affiliation:

1. Hospital Clínic, Institut d’investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain;

2. Institut Català d’Oncologia I Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain;

3. Hospital Virgen de las Nieves, Granada, Spain;

4. Institut Català d’Oncologia-Hospitalet, Barcelona, Spain;

5. Hospital Ramón y Cajal, Madrid, Spain;

6. Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain;

7. Hospital Universitario San Carlos, Madrid, Spain;

8. Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain;

9. Hospital La Fe, Valencia, Spain;

10. Hospital Son Llatzer, Palma de Mallorca, Spain;

11. Hospital Vall d’Hebron, Barcelona, Spain;

12. Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer y Centro Regional de Hemodonación, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain;

13. Hospital Clínico Lozano Blesa, Zaragoza, Spain;

14. Hospital Josep Trueta, Girona, Spain;

15. Hospital Mútua de Terrassa, Terrassa, Spain;

16. Hospital Puerta de Hierro, Madrid, Spain;

17. Complejo Hospitalario de Navarra, Pamplona, Spain;

18. Hospital Cabueñes, Gijón, Spain;

19. Hospital Central de Asturias, Oviedo, Spain;

20. Hospital Virgen de la Salud, Toledo, Spain;

21. Hospital Universitario 12 de Octubre, Madrid, Spain;

22. Clínica Universidad de Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain; and

23. Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain

Abstract

Key PointsVRD was effective and well tolerated before ASCT; 33.4% complete response/28.8% minimal residual disease–negative after 6 induction cycles. Responses deepened with VRD throughout induction and over the course of treatment with few discontinuations due to toxicity.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference45 articles.

1. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival;Lahuerta;J Clin Oncol,2008

2. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 trials;Harousseau;J Clin Oncol,2009

3. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma;van de Velde;Haematologica,2007

4. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation;Martinez-Lopez;Blood,2011

5. D’Souza A , FrethamC. Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR summary slides, 2018. https://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/Documents/2018%20Summary%20Slides%20-%20final%20-%20for%20web%20posting.pptx?Web=1. Accessed 16 September 2019.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3